Neutrophil dynamics during concurrent chemotherapy and G-CSF administration: Mathematical modelling guides dose optimisation to minimise neutropenia. (21st November 2015)

• Record Type: Journal Article
• Authors: Craig, Morgan; Humphries, Antony R.; Nekka, Fahima; Bélair, Jacques; Li, Jun; Mackey, Michael C.
• Is Part Of: Journal of theoretical biology. Volume 385(2015)
• Page Start: 77
• Page End: 89
• Publication Date: 2015-11-21
• Subjects: Myelopoeisis -- Physiological mathematical modelling -- Pharmacokinetics/pharmacodynamics; Biology -- Periodicals; Biological Science Disciplines -- Periodicals; Biology -- Periodicals; Biologie -- Périodiques; Theoretische biologie; Biology; Periodicals; 571.05
• DOI: 10.1016/j.jtbi.2015.08.015
• Languages: English
• ISSNs: 0022-5193

Abstract

Abstract: The choice of chemotherapy regimens is often constrained by the patient's tolerance to the side effects of chemotherapeutic agents. This dose-limiting issue is a major concern in dose regimen design, which is typically focused on maximising drug benefits. Chemotherapy-induced neutropenia is one of the most prevalent toxic effects patients experience and frequently threatens the efficient use of chemotherapy. In response, granulocyte colony-stimulating factor (G-CSF) is co-administered during chemotherapy to stimulate neutrophil production, increase neutrophil counts, and hopefully avoid neutropenia. Its clinical use is, however, largely dictated by trial and error processes. Based on up-to-date knowledge and rational considerations, we develop a physiologically realistic model to mathematically characterise the neutrophil production in the bone marrow which we then integrate with pharmacokinetic and pharmacodynamic (PKPD) models of a chemotherapeutic agent and an exogenous form of G-CSF (recombinant human G-CSF, or rhG-CSF). In this work, model parameters represent the average values for a general patient and are extracted from the literature or estimated from available data. The dose effect predicted by the model is confirmed through previously published data. Using our model, we were able to determine clinically relevant dosing regimens that advantageously reduce the number of rhG-CSF administrations compared to original studies while significantly improving the neutropenia status. More particularly, we determine that it could be beneficial to delay the first administration of rhG-CSF to day seven post-chemotherapy and reduce the number of administrations from ten to three or four for a patient undergoing 14-day periodic chemotherapy. Abstract : Highlights: An integrated model of physiology and anti-cancer therapy. An up-to-date physiological DDE model of myelopoiesis. Rational parameter estimation determined from a variety of studies. Successfully captures main behaviour of the interplay of physiology and chemotherapy. Improved therapeutic outcomes through delayed and reduced number of administrations of G-CSF.